



## Recent Advances in Novel Pneumococcal Vaccines

Guest Editor:

**Dr. Jose Enrique Yuste**

Spanish Pneumococcal  
Reference Laboratory, National  
Center for Microbiology, Instituto  
de Salud Carlos III, Madrid, Spain

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

Prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* is essential to avoid the high morbidity and mortality rates worldwide by this devastating human pathogen. New broader pneumococcal conjugate vaccines (PCVs) may partially solve this problem for a limited period of time although, alternative vaccines based in conserved and immunogenic protein antigens, DNA-based vaccines, whole cell vaccines and others preventive options that may increase the protection coverage are needed. This Special Issue will focus in the characterization of novel vaccines to prevent pneumococcal infections including the evaluation of the host immune response of newer PCVs and non-capsular based vaccines. The impact of vaccines reducing pneumococcal carriage and disease would be of interest. Contributions in the areas of microbiology, immunology and clinical epidemiology related to novel pneumococcal vaccines are welcome.

Dr. Jose Yuste  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)